{"id":71441,"date":"2026-05-20T11:35:00","date_gmt":"2026-05-20T11:35:00","guid":{"rendered":"https:\/\/medsbase.com\/hmg-peptide\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"hmg-peptide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/hmg-peptide\/","title":{"rendered":"HMG (Human Menopausal Gonadotropin \/ Menotropin) \u2014 Pharmaceutical Grade"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Quick Answer \u2014 What is HMG (pharmaceutical-grade)?<\/h3>\n<p style=\"margin: 0;\"><strong>HMG<\/strong> (Gonadotrofina Menop\u00e1usica Humana, tamb\u00e9m conhecida como <strong>menotropina<\/strong>; CAS 61489-71-2) \u00e9 uma prepara\u00e7\u00e3o glicoproteica hormonal derivada da urina contendo igual bioatividade de LH e FSH (75 UI de LH + 75 UI de FSH por frasco, a propor\u00e7\u00e3o padr\u00e3o 1:1). Purificada a partir da urina de mulheres na p\u00f3s-menopausa \u2014 cuja produ\u00e7\u00e3o de gonadotrofinas hipofis\u00e1rias est\u00e1 naturalmente elevada pela aus\u00eancia de inibi\u00e7\u00e3o por feedback negativo \u2014 a hMG \u00e9 o <strong>agonista dual LHCGR + FSHR<\/strong> in endocrine pharmacology and the reference tool for protocols that need simultaneous Leydig-cell \/ theca-cell steroidogenesis (LH side) and Sertoli-cell \/ granulosa-cell action (FSH side). The supplied pharmaceutical-grade material is the urinary-extracted glycoform at \u226599% HPLC purity. <em>For clinical studies use only.<\/em> Diferente das prepara\u00e7\u00f5es cl\u00ednicas de menotropina (Menopur, Menogon, Repronex).<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe do Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prepara\u00e7\u00e3o de horm\u00f4nio glicoproteico \u2014 mistura fixa 1:1 de bioatividade de LH e FSH; agonista duplo de receptor LH\/CG (LHCGR) + receptor FSH (FSHR); prepara\u00e7\u00e3o de horm\u00f4nio pept\u00eddico<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome Qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Gonadotrofina Menop\u00e1usica Humana (Menotropina; prepara\u00e7\u00e3o extra\u00edda de urina; sin\u00f4nimos: hMG, urofollitropina-com-LH, gonadotrofina menop\u00e1usica)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">61489-71-2 (menotropina \/ hMG prepara\u00e7\u00e3o mista)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Componentes Ativos<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>LH<\/strong> (horm\u00f4nio luteinizante, heterod\u00edmero ~30 kDa; \u03b1 92 aa + \u03b2 121 aa, glicosilado) \u2014 75 UI por frasco; <strong>FSH<\/strong> (horm\u00f4nio fol\u00edculo-estimulante, heterod\u00edmero ~30 kDa; \u03b1 92 aa + \u03b2 111 aa, glicosilado) \u2014 75 UI por frasco. A subunidade \u03b1 \u00e9 compartilhada entre LH, FSH, HCG e TSH; as subunidades \u03b2 conferem especificidade ao receptor. Ambas as gonadotrofinas s\u00e3o extensamente N- e O-glicosiladas.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Raz\u00e3o de Bioatividade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Atividade LH:FSH = 1:1 (a raz\u00e3o padr\u00e3o de hMG desde a padroniza\u00e7\u00e3o de pot\u00eancia no final dos anos 1990; ambas as atividades medidas por bioensaio da OMS contra padr\u00f5es de refer\u00eancia internacionais)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>HCG Co-Purification (studies-relevant)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Uma caracter\u00edstica das prepara\u00e7\u00f5es de hMG derivadas de urina: an\u00e1lises composicionais publicadas relatam que aproximadamente <strong>95% da bioatividade mediada pelo receptor de LH in vivo \u00e9 atribu\u00edvel ao tra\u00e7o de HCG co-purificado da urina p\u00f3s-menopausa<\/strong> (Wolfenson et\u00a0al. 2005 and others). HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h half-life vs LH&#8217;s ~20 min \u2014 so even small HCG amounts dominate the in-vivo LH-equivalent signal. Users should be aware of this when comparing hMG to pure recombinant LH (Luveris) preparations.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mecanismo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">A\u00e7\u00e3o agonista dupla sobre GPCR. <strong>LHCGR<\/strong> (Acoplado a Gs, c\u00e9lulas de Leydig \/ teca \/ granulosa \/ corpo l\u00fateo) \u2192 cascata cAMP-PKA-StAR-CYP17A1 \u2192 bioss\u00edntese de andr\u00f3genos. <strong>FSHR<\/strong> (Acoplado a Gs, c\u00e9lulas de Sertoli em homens \/ c\u00e9lulas da granulosa em mulheres) \u2192 cascata cAMP-PKA-CYP19A1\/aromatase \u2192 suporte \u00e0 espermatog\u00eanese (homem) ou convers\u00e3o de andr\u00f3geno em estrog\u00eanio + matura\u00e7\u00e3o folicular (mulher). A ativa\u00e7\u00e3o dupla \u00e9 o que distingue o hMG das prepara\u00e7\u00f5es de LH puro (Luveris \/ rLH) ou FSH puro (Gonal-F \/ Puregon \/ rFSH).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prepara\u00e7\u00e3o mista \u2014 tanto LH quanto FSH s\u00e3o glicoprote\u00ednas heterodim\u00e9ricas. Subunidade \u03b1 (compartilhada) ~92 aa, id\u00eantica em LH\/FSH\/HCG\/TSH. Subunidade \u03b2 do LH ~121 aa, subunidade \u03b2 do FSH ~111 aa. Sequ\u00eancias completas dispon\u00edveis no UniProt: LH\u03b2 (P01229), FSH\u03b2 (P01225), GPH\u03b1 (P01215).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Prepara\u00e7\u00e3o mista de glicoprote\u00edna extra\u00edda da urina \u2014 FSH (\u03b1 92aa + \u03b2 111aa) + LH (\u03b1 92aa + \u03b2 121aa) heterod\u00edmeros em propor\u00e7\u00e3o de bioatividade ~1:1. Sem f\u00f3rmula molecular \u00fanica devido ao padr\u00e3o heterog\u00eaneo de glicosila\u00e7\u00e3o na prepara\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Meia-vida plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Atividade do FSH: meia-vida terminal ~30\u201340 h (impulsionada pela sialila\u00e7\u00e3o, semelhante a outros horm\u00f4nios glicoproteicos). Atividade do LH no hMG: nominalmente ~10\u201320 h (mas na pr\u00e1tica impulsionada pela fra\u00e7\u00e3o de HCG copurificada com meia-vida de 33\u201337 h \u2014 ver nota acima sobre copurifica\u00e7\u00e3o de HCG).<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder with mannitol or lactose stabilising matrix; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC); bioensaio da WHO confirma atividade de LH e FSH na dosagem rotulada de 75 UI cada. COA dispon\u00edvel mediante solicita\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Reconstitua em \u00e1gua bacteriost\u00e1tica a 1,0 mL por frasco \u2192 75 UI de LH + 75 UI de FSH por mL de estoque de trabalho; outras dilui\u00e7\u00f5es conforme protocolo. O p\u00f3 se dissolve rapidamente com agita\u00e7\u00e3o suave. <strong>N\u00e3o agite; n\u00e3o use vortex<\/strong> \u2014 a mistura de alta cisalhamento dissocia os heterod\u00edmeros \u03b1\/\u03b2 de ambos os componentes LH e FSH.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C fechado para estoque de trabalho de curto prazo; \u221220 \u00b0C para armazenamento de longo prazo (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). Reconstitu\u00eddo: 2\u20138 \u00b0C, use dentro de ~30 dias. Proteja da luz. <strong>N\u00e3o congele o material reconstitu\u00eddo<\/strong> \u2014 ciclos de congelamento-descongelamento dissociam os heterod\u00edmeros \u03b1\/\u03b2 de LH e FSH e destroem a bioatividade.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O que \u00e9 HMG (Menotropina)?<\/h2>\n<p><strong>HMG<\/strong> \u2014 Gonadotrofina Menop\u00e1usica Humana, tamb\u00e9m conhecida como <strong>menotropina<\/strong> (CAS 61489-71-2) \u2014 is a urinary-derived glycoprotein-hormone preparation containing equal amounts of LH (luteinising hormone) and FSH (follicle-stimulating hormone) bioactivity, standardised at 75 IU of each per vial. It is purified by ion-exchange and gel-filtration chromatography from the pooled urine of postmenopausal women, who have naturally elevated pituitary gonadotropin output (LH and FSH typically 50\u2013100+ mIU\/mL each) due to the loss of ovarian negative-feedback inhibition that accompanies menopause. The &#8220;menopausal&#8221; in the name refers to this source: postmenopausal urine is the most concentrated natural source of LH and FSH available for industrial-scale purification, and hMG has been produced from this source since the early 1960s (the original Cesare Serono-developed Pergonal preparation). The compositional refinement of hMG has evolved substantially over the decades \u2014 earlier preparations had highly variable LH:FSH ratios and significant protein-impurity loads; modern preparations (the basis of our pharmaceutical-grade material) are standardised at 75:75 IU bioactivity per vial with \u226599% HPLC purity. hMG is the canonical dual-gonadotropin pharmacological tool. Where HCG selectively activates the LHCGR, where pure-LH (recombinant Luveris) selectively activates the LHCGR at physiological half-life, where pure-FSH (recombinant Gonal-F \/ Puregon) selectively activates the FSHR, hMG activates both receptors simultaneously at a fixed 1:1 ratio. The two receptors are expressed on different cell populations within the gonad \u2014 LHCGR on Leydig cells \/ theca cells \/ luteinised granulosa \/ corpus luteum; FSHR on Sertoli cells \/ mural granulosa \u2014 so dual activation produces a complete physiological gonadotropin stimulus that more closely mimics endogenous mid-cycle pituitary output than either receptor activated alone. <strong>A studies-relevant nuance: HCG co-purification.<\/strong> Published compositional analyses of urinary-derived hMG preparations report that the bulk of the in-vivo LH-receptor bioactivity is actually attributable to trace HCG co-purified from postmenopausal urine \u2014 approximately 95% of LH-receptor-mediated bioactivity by some analyses (Wolfenson et\u00a0al., 2005). This is because HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h plasma half-life versus LH&#8217;s ~20 min, so even small HCG amounts dominate the cumulative in-vivo LH-equivalent signal. This is part of why hMG produces sustained Leydig-cell stimulation despite the nominal &#8220;LH activity&#8221; of LH itself being short-lived. For protocols where this distinction matters (pure-LH pharmacology vs HCG-contaminated mixed-LH signal), recombinant LH (Luveris) is the cleaner tool; for protocols where dual LHCGR + FSHR activation at physiological 1:1 ratio is the goal, hMG is the canonical reference. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Ativa\u00e7\u00e3o Dupla de LHCGR + FSHR<\/h2>\n<p>O mecanismo do hMG \u00e9 a soma dual de suas duas atividades componentes, ambas bem caracterizadas na farmacologia end\u00f3crina:<\/p>\n<ul>\n<li><strong>LH (e HCG copurificado) \u2192 ativa\u00e7\u00e3o do LHCGR<\/strong> \u2014 O componente LH (e o tra\u00e7o de HCG que copurifica da urina p\u00f3s-menopausa) liga-se ao receptor LH\/CG nas c\u00e9lulas de Leydig (test\u00edculo) e c\u00e9lulas da teca\/granulosa\/luteais (ov\u00e1rio). O acoplamento Gs aumenta o cAMP, ativa a PKA, regula positivamente o transporte mitocondrial de colesterol mediado por StAR e induz as enzimas esteroidog\u00eanicas CYP11A1\/CYP17A1\/3\u03b2-HSD\/17\u03b2-HSD \u2014 impulsionando a bioss\u00edntese de novo de testosterona (masculino) ou androstenediona (feminino).<\/li>\n<li><strong>FSH \u2192 ativa\u00e7\u00e3o do FSHR<\/strong> \u2014 O componente FSH liga-se ao receptor de FSH nas c\u00e9lulas de Sertoli (test\u00edculo) e c\u00e9lulas da granulosa mural (ov\u00e1rio). O FSHR tamb\u00e9m \u00e9 acoplado a Gs, mas seu programa downstream \u00e9 distinto: nas c\u00e9lulas de Sertoli, a ativa\u00e7\u00e3o do FSHR impulsiona a prote\u00edna de liga\u00e7\u00e3o a andr\u00f3genos (ABP), a inibina B e o programa de suporte estrutural que sustenta a espermatog\u00eanese; nas c\u00e9lulas da granulosa, a ativa\u00e7\u00e3o do FSHR impulsiona a CYP19A1 (aromatase), convertendo andr\u00f3genos derivados das c\u00e9lulas da teca em estrog\u00eanios e promove a matura\u00e7\u00e3o folicular atrav\u00e9s dos est\u00e1gios antral e pr\u00e9-ovulat\u00f3rio.<\/li>\n<li><strong>Modelo combinado de duas c\u00e9lulas e duas gonadotropinas<\/strong> \u2014 O quadro end\u00f3crino cl\u00e1ssico. No test\u00edculo masculino, as c\u00e9lulas de Leydig estimuladas por LH produzem testosterona, que difunde para as c\u00e9lulas de Sertoli adjacentes, onde a prote\u00edna de liga\u00e7\u00e3o a andr\u00f3genos induzida por FSH e a maquinaria metab\u00f3lica das c\u00e9lulas de Sertoli a convertem no microambiente de alta testosterona intratesticular que a espermatog\u00eanese requer. No ov\u00e1rio feminino, as c\u00e9lulas da teca estimuladas por LH produzem andr\u00f3genos, que difundem para as c\u00e9lulas da granulosa adjacentes, onde a aromatase induzida por FSH os converte em estrog\u00eanios. O modelo de duas c\u00e9lulas e duas gonadotropinas \u00e9 o quadro can\u00f4nico, e o hMG \u00e9 a ferramenta farmacol\u00f3gica can\u00f4nica para engajar ambas as metades simultaneamente.<\/li>\n<li><strong>Dessensibiliza\u00e7\u00e3o do receptor e taquifilaxia<\/strong> \u2014 Both LHCGR and FSHR undergo arrestin-mediated desensitization after sustained agonist exposure. Repeated high-dose hMG dosing can produce receptor downregulation \u2014 a well-documented phenomenon in published gonadotropin-pharmacology studies relevant to chronic-dosing protocols.<\/li>\n<li><strong>Feedback hipot\u00e1lamo-hipofis\u00e1rio<\/strong> \u2014 As with HCG, hMG-driven gonadal steroid output feeds back to the hypothalamus and pituitary to suppress endogenous GnRH and LH\/FSH secretion. In the context of HPG-suppression studies (testosterone replacement, AAS exposure, pharmacological GnRH antagonism), hMG bypasses the hypothalamic-pituitary blockade by acting directly at the gonadal receptors \u2014 preserving both Leydig-cell function (LH side) and Sertoli-cell \/ spermatogenesis-support function (FSH side) simultaneously, which is what distinguishes hMG from pure-HCG protocols in this context.<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of hMG broadly mirrors that of its components: FSH activity persists with 30\u201340 h terminal half-life, LH-equivalent activity is dominated by the long-half-life co-purified HCG (33\u201337 h), and the combined preparation produces sustained 24\u201372 h dual gonadotropin stimulation per dose. Typical protocol dosing is 75\u2013225 IU SC daily in rodent or human-subject studies \u2014 equivalent to 1\u20133 vials of the 75 IU strength. <\/p>\n<h2>Published Evidence<\/h2>\n<p>hMG is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia das gonadotrofinas \u2014 a refer\u00eancia can\u00f4nica de duplo receptor<\/strong> \u2014 most-cited dual LHCGR + FSHR agonist in published gonadotropin studies; standard reference compound for dissecting LH-only vs FSH-only vs combined gonadotropin signalling<\/li>\n<li><strong>Spermatogenesis induction studies<\/strong> \u2014 in hypogonadotropic-hypogonadism rodent models, hMG (with or without supplementary HCG) is the canonical tool for inducing spermatogenesis by restoring both Leydig-cell testosterone production and Sertoli-cell FSH support; standard protocol cycle is 75\u2013150 IU SC three times per week for 6\u201324 months in clinical-translational studies<\/li>\n<li><strong>Female ovarian-stimulation studies<\/strong> \u2014 the historical foundation tool of in-vitro fertilisation studies; hMG drives follicular development through the antral and pre-ovulatory stages in published ovulation-induction protocols, typically combined with HCG as ovulation trigger; widely used in studies on polycystic ovary syndrome (PCOS), unexplained infertility, and assisted reproductive technologies<\/li>\n<li><strong>Two-cell two-gonadotropin model studies<\/strong> \u2014 the canonical framework of gonadal steroidogenesis pharmacology; hMG is the standard tool for activating both halves of the model simultaneously; published Sertoli-Leydig co-culture and theca-granulosa co-culture uses hMG to recapitulate the physiological dual-receptor stimulus<\/li>\n<li><strong>HPG-axis suppression-recovery<\/strong> \u2014 in published studies models where endogenous LH\/FSH has been suppressed (by exogenous testosterone, AAS exposure, or GnRH antagonism), hMG preserves both Leydig-cell function and Sertoli-cell function by direct gonadal receptor activation \u2014 distinguishing it from HCG-only protocols which preserve only LH-side function and risk Sertoli-cell atrophy<\/li>\n<li><strong>Farmacologia comparativa vs LH puro \/ FSH pura \/ HCG<\/strong> \u2014 as compara\u00e7\u00f5es publicadas frente a frente de hMG versus LH recombinante (Luveris), FSH recombinante (Gonal-F \/ Puregon), HCG recombinante (Ovidrel) e v\u00e1rias combina\u00e7\u00f5es s\u00e3o extensas; o hMG \u00e9 a refer\u00eancia mista 1:1 derivada da urina contra a qual todos esses s\u00e3o avaliados<\/li>\n<li><strong>Desenvolvimento folicular e biologia das c\u00e9lulas da granulosa<\/strong> \u2014 published ex-vivo follicular culture and primary granulosa-cell uses hMG to drive simultaneous theca-cell androgen production and granulosa-cell aromatase induction \u2014 the most physiologically relevant in-vitro stimulus available<\/li>\n<li><strong>Biologia do corpo l\u00fateo<\/strong> \u2014 sustained LHCGR activation by the LH component (and co-purified HCG) maintains corpus-luteum function and progesterone production; used in studies on the luteal phase and luteo-placental transition<\/li>\n<\/ul>\n<p>For broader context on HPG-axis and reproductive-system peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/pt-br\/hcg-peptide\/\">HCG (Gonadotrofina Cori\u00f4nica Humana)<\/a> (agonista puro do LHCGR \u2014 compara\u00e7\u00e3o direta; apenas atividade do lado do LH), <a href=\"https:\/\/medsbase.com\/pt-br\/kisspeptin-10\/\">Kisspeptina-10<\/a> (o agonista Kiss1R hipotal\u00e2mico upstream \u2014 impulsiona a pulsatileidade end\u00f3gena do GnRH), <a href=\"https:\/\/medsbase.com\/pt-br\/pt-141\/\">PT-141 (Bremelanotide)<\/a> (melanocortin-receptor pharmacology \u2014 sexual-function studies), and <a href=\"https:\/\/medsbase.com\/pt-br\/oxytocin-acetate\/\">Acetato de Ocitocina<\/a> (horm\u00f4nio pept\u00eddico da hip\u00f3fise posterior). Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">peptides &amp; compounds catalog<\/a>. <\/p>\n<h2>Concentra\u00e7\u00f5es e Dosagens Dispon\u00edveis<\/h2>\n<p>MedsBase stocks HMG (urinary-extracted menotropin) in a single lyophilized vial strength calibrated to the standard 1:1 LH:FSH bioactivity unit. The vial is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de Uso T\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>75 UI de LH + 75 UI de FSH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength (the international-reference unit dose) \u2014 single-dose dual-gonadotropin stimulation, spermatogenesis-induction protocols (75\u2013225 IU SC three times per week), ovarian-stimulation studies, two-cell two-gonadotropin co-culture stimulation, comparative pharmacology vs recombinant pure-LH and pure-FSH preparations<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The 75:75 IU vial is the international-reference dose unit and the format used in essentially all published gonadotropin studies and clinical practice. Multiple-vial dosing (150 IU, 225 IU per administration) is standard for higher-dose protocols. The 30-vial pack is the more economical purchase per-IU for extended-cycle or multi-cohort protocols. <\/p>\n<h2>Como Comparar \u2014 HMG vs HCG<\/h2>\n<p><a href=\"https:\/\/medsbase.com\/pt-br\/hcg-peptide\/\">HCG<\/a> e hMG s\u00e3o as duas prepara\u00e7\u00f5es de gonadotrofinas derivadas da urina neste cat\u00e1logo, e elas atuam no sistema de receptores de gonadotrofinas de maneiras mecanicamente distintas. HCG \u00e9 um <em>agonista puro<\/em> do receptor LH\/CG \u2014 ativa\u00e7\u00e3o apenas das c\u00e9lulas de Leydig\/c\u00e9lulas da teca. hMG \u00e9 a prepara\u00e7\u00e3o <em>dual<\/em> LH + FSH preparation \u2014 engages both halves of the two-cell two-gonadotropin model simultaneously. The choice between them in studies depends on whether the protocol needs LH-side activation alone or combined LH-side + FSH-side activation. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HMG (Menotropina)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HCG<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Composi\u00e7\u00e3o<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mistura fixa 1:1: LH 75 UI + FSH 75 UI por frasco (+ tra\u00e7os de HCG que dominam o sinal in-vivo equivalente ao LH)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">HCG puro (extra\u00eddo da urina) \u2014 glicoprote\u00edna \u00fanica<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Receptores ativados<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">LHCGR <em>e<\/em> FSHR \u2014 ativa\u00e7\u00e3o dual de receptores de gonadotropina<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">LHCGR apenas \u2014 receptor \u00fanico<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Fonte<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Urina p\u00f3s-menopausa<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Urina de gestantes (uHCG) ou c\u00e9lulas CHO recombinantes (rHCG)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Spermatogenesis induction (preserves Sertoli-cell function), ovarian follicular stimulation, two-cell two-gonadotropin model studies, dual-receptor pharmacology<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Leydig-cell-only stimulation, ovulation triggering (LH-surge mimic), Leydig-cell-specific HPG-suppression-recovery, LHCGR pharmacology<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">FSH ~30\u201340 h; atividade equivalente a LH dominada por HCG copurificado (33\u201337 h)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">33\u201337 h (fase terminal)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">75\u2013225 UI SC (1\u20133 frascos) por administra\u00e7\u00e3o; 3\u00d7\/semana em protocolos cr\u00f4nicos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">500\u20135.000 UI SC\/IM (bolus \u00fanico); 250\u2013500 UI\/dia em protocolos cr\u00f4nicos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Unidade de dosagem por frasco<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">75 UI de bioatividade (dose unidade de refer\u00eancia internacional)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5.000 ou 10.000 UI de bioatividade<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Status WADA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Proibido em todos os momentos para atletas masculinos (S2 \u2014 Horm\u00f4nios Pept\u00eddicos)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Proibido em todos os momentos para atletas masculinos (S2 \u2014 Horm\u00f4nios Pept\u00eddicos); isen\u00e7\u00e3o para atletas femininas<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on dual LHCGR + FSHR activation, spermatogenesis induction, or the canonical two-cell two-gonadotropin model, hMG is the standard reference compound. For studies focused on Leydig-cell-only stimulation, ovulation triggering, or HCG-specific LHCGR pharmacology, <a href=\"https:\/\/medsbase.com\/pt-br\/hcg-peptide\/\">HCG<\/a> \u00e9 a ferramenta mais direcionada. Veja tamb\u00e9m <a href=\"https:\/\/medsbase.com\/pt-br\/kisspeptin-10\/\">Kisspeptina-10<\/a> for upstream hypothalamic Kiss1R \/ GnRH-pulsatility studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com nosso <a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, preservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo, congele frascos fechados a \u221220 \u00b0C (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). O bolo liofilizado \u00e9 estabilizado com manitol ou lactose e \u00e9 razoavelmente tolerante \u00e0 exposi\u00e7\u00e3o breve \u00e0 temperatura ambiente durante o manuseio, mas deve ser devolvido \u00e0 refrigera\u00e7\u00e3o imediatamente. Proteja da luz. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> for each 75 IU vial, inject 1.0\u00a0mL of bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake) \u2014 this yields a working stock of 75 IU LH + 75 IU FSH per mL. For protocols that need higher concentrations (multi-vial pooling for higher single-dose), reconstitute 2\u20133 vials with the same 1.0\u00a0mL diluent total to give 150\u2013225 IU\/mL. <strong>Agite suavemente para dissolver \u2014 n\u00e3o agite vigorosamente, n\u00e3o use v\u00f3rtex.<\/strong> A mistura de alta cisalhamento dissocia os heterod\u00edmeros \u03b1\/\u03b2 de ambos os componentes de LH e FSH e destr\u00f3i a bioatividade do receptor de gonadotrofina. O bolo de liofiliza\u00e7\u00e3o \u00e0 base de manitol geralmente se dissolve em 30\u201360 segundos com agita\u00e7\u00e3o suave. <strong>Regras cr\u00edticas de armazenamento para material reconstitu\u00eddo:<\/strong> uma vez reconstitu\u00eddo, armazene a 2\u20138 \u00b0C e use dentro de 30 dias. <strong>N\u00e3o congele hMG reconstitu\u00eddo<\/strong> \u2014 freeze-thaw cycles dissociate the LH and FSH \u03b1\/\u03b2 heterodimers (the same physical-chemistry constraint as HCG) and irreversibly destroy bioactivity. Protect from light. Discard if cloudiness, particulates, or marked colour change appears. For protocols requiring multiple aliquots, prepare aliquots at the time of reconstitution and store at 2\u20138 \u00b0C separately rather than freezing. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>Qual \u00e9 a diferen\u00e7a entre HMG e HCG?<\/h3>\n<p><a href=\"https:\/\/medsbase.com\/pt-br\/hcg-peptide\/\">HCG<\/a> is a pure LH\/CG-receptor agonist \u2014 single glycoprotein hormone (CAS 9002-61-3) that binds and activates only the LHCGR on Leydig \/ theca \/ granulosa \/ luteal cells. hMG is a 1:1 mixture of LH and FSH bioactivity \u2014 distinct glycoprotein hormones (combined CAS 61489-71-2) that bind both the LHCGR (LH side) and the FSHR (FSH side). The clinical and studies consequence is that hMG produces dual-receptor stimulation that engages both halves of the two-cell two-gonadotropin model (Leydig + Sertoli in males; theca + granulosa in females), where HCG produces single-receptor stimulation of the LHCGR side only. <\/p>\n<h3>What is the HCG co-purification in hMG, and why does it matter for studies?<\/h3>\n<p>An\u00e1lises composicionais publicadas de prepara\u00e7\u00f5es de hMG derivadas da urina relatam que aproximadamente <strong>95% da bioatividade mediada pelo receptor de LH in vivo<\/strong> is actually attributable to trace HCG co-purified from postmenopausal urine, rather than to LH itself (Wolfenson et\u00a0al., 2005). This is because HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h plasma half-life vs LH&#8217;s ~20 min \u2014 so even small amounts of co-purified HCG dominate the cumulative in-vivo LH-equivalent signal. For protocols where this distinction matters (e.g., comparing pure-LH pharmacology vs HCG-contaminated mixed-LH signal), <strong>LH recombinante (Luveris)<\/strong> \u00e9 a ferramenta mais limpa. Para protocolos onde a ativa\u00e7\u00e3o dual de LHCGR + FSHR em propor\u00e7\u00e3o fixa 1:1 \u00e9 o objetivo, o hMG \u00e9 a refer\u00eancia can\u00f4nica. <\/p>\n<h3>Por que o hMG \u00e9 obtido da urina de mulheres p\u00f3s-menop\u00e1usicas?<\/h3>\n<p>Mulheres p\u00f3s-menop\u00e1usicas perdem a inibi\u00e7\u00e3o por feedback negativo ovariano do eixo hipot\u00e1lamo-hipofis\u00e1rio, o que aumenta drasticamente a produ\u00e7\u00e3o de LH e FSH pela hip\u00f3fise \u2014 os n\u00edveis s\u00e9ricos t\u00edpicos de LH e FSH p\u00f3s-menop\u00e1usicos s\u00e3o de 50\u2013100+ mUI\/mL cada, uma ordem de magnitude maior que os valores pr\u00e9-menop\u00e1usicos. Ambos os horm\u00f4nios s\u00e3o ent\u00e3o eliminados renalmente na urina em forma concentrada. A urina p\u00f3s-menop\u00e1usica coletada \u00e9, portanto, a fonte natural mais concentrada de LH + FSH para extra\u00e7\u00e3o em escala industrial. A ind\u00fastria de hMG foi constru\u00edda sobre esse insight no in\u00edcio dos anos 1960 (Pergonal foi a prepara\u00e7\u00e3o original da Serono) e continua at\u00e9 hoje, embora grande parte do mercado cl\u00ednico tenha migrado para prepara\u00e7\u00f5es de LH puro recombinante e FSH puro recombinante. <\/p>\n<h3>What published dose ranges have been used in studies?<\/h3>\n<p>Single-dose protocol use is typically 75\u2013225 IU SC per administration (1\u20133 vials of the 75 IU strength), with 3\u00d7\/week or daily dosing in chronic protocols. Spermatogenesis-induction protocols in published hypogonadotropic-hypogonadism studies typically use 75\u2013150 IU 3\u00d7\/week for 6\u201324 months in combination with HCG (the HCG provides additional Leydig-cell stimulation). In-vitro Sertoli-cell or granulosa-cell culture protocols typically use 1\u201310 IU\/mL in growth medium. Users should consult primary literature appropriate to the species, model, and endpoint. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre hMG e FSH recombinante puro (Gonal-F\/Puregon)?<\/h3>\n<p>FSH recombinante puro (follitropina alfa\/Gonal-F; follitropina beta\/Puregon; produzida em c\u00e9lulas CHO a partir de cDNAs clonados de FSH \u03b1 e \u03b2) cont\u00e9m <em>apenas<\/em> FSH bioactivity \u2014 no LH, no HCG. hMG contains both LH and FSH bioactivity at 1:1 ratio (plus trace HCG). For protocols that need pure FSHR activation isolated from LHCGR signalling, recombinant FSH is the correct tool. For protocols that need combined dual-receptor activation at physiological ratio, hMG is the correct tool. Published head-to-head trials in ovarian-stimulation have compared the two with broadly equivalent follicular-development endpoints but with subtly different oestradiol-response profiles (hMG tends to produce slightly higher mid-cycle oestradiol due to the LH-side androgen substrate it provides for granulosa-cell aromatase). <\/p>\n<h3>Por que o hMG reconstitu\u00eddo n\u00e3o pode ser congelado?<\/h3>\n<p>Pela mesma raz\u00e3o que o HCG \u2014 tanto o LH quanto o FSH s\u00e3o heterod\u00edmeros de duas subunidades associadas n\u00e3o covalentemente (\u03b1 + \u03b2 cada). A intera\u00e7\u00e3o \u03b1\/\u03b2 \u00e9 est\u00e1vel no liofilizado (sem \u00e1gua para perturbar a intera\u00e7\u00e3o) e est\u00e1vel em solu\u00e7\u00e3o aquosa refrigerada a 2\u20138 \u00b0C (a cin\u00e9tica de dissocia\u00e7\u00e3o \u00e9 lenta em baixa temperatura). Mas a forma\u00e7\u00e3o de cristais de gelo durante o congelamento separa fisicamente as subunidades, e elas se reassociam de forma ineficiente ap\u00f3s o descongelamento. O resultado \u00e9 que o hMG congelado e descongelado ret\u00e9m uma grande fra\u00e7\u00e3o de imunorreatividade, mas perde uma grande fra\u00e7\u00e3o de bioatividade. O hMG liofilizado pode ser congelado e \u00e9 est\u00e1vel a \u221220 \u00b0C; o hMG reconstitu\u00eddo n\u00e3o pode. <\/p>\n<h3>Qual \u00e9 o status regulat\u00f3rio do hMG pela WADA?<\/h3>\n<p>hMG \/ menotropin is on the World Anti-Doping Agency (WADA) Prohibited List under class S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). It is prohibited at all times \u2014 both in-competition and out-of-competition \u2014 for male athletes. Users conducting human-subject studies with hMG need to be aware of this regulatory status. For clinical in-vitro and rodent in-vivo studies the WADA status is informational only. <\/p>\n<h3>How does this pharmaceutical-grade hMG compare with the branded clinical preparations (Menopur, Menogon, Repronex)?<\/h3>\n<p>The branded clinical preparations are urinary-extracted menotropin (Menopur, Menogon, Repronex; the historical Pergonal preparation has been largely discontinued) packaged under various manufacturer SKUs for clinical use in assisted reproductive technologies. The pharmaceutical-grade hMG supplied here is the same urinary-extracted preparation at \u226599% HPLC purity, supplied without a clinical-use label and intended for clinical studies only. Users seeking clinical-use menotropin should obtain it through a clinical supply chain; users seeking pharmaceutical-grade material for in-vitro receptor pharmacology, rodent in-vivo work, or other clinical applications can use the material supplied here. <\/p>\n<h3>Can hMG be combined with HCG, Kisspeptin-10, or testosterone in protocols?<\/h3>\n<p>Yes \u2014 these compounds target different layers of the HPG axis and are commonly combined in published studies. The most-published combinations are hMG + HCG (the standard clinical and protocol for spermatogenesis induction in hypogonadotropic-hypogonadism models \u2014 hMG provides FSH-side support, additional HCG provides supplemental LH-side stimulation); hMG + <a href=\"https:\/\/medsbase.com\/pt-br\/kisspeptin-10\/\">Kisspeptina-10<\/a> (upstream + downstream dissection \u2014 kisspeptin drives endogenous GnRH while hMG provides direct gonadal stimulation); hMG + exogenous testosterone (for HPG-suppression-recovery, where the testosterone suppresses endogenous LH\/FSH and hMG bypasses the suppression by acting directly at the gonad). Reconstitute each separately and follow each compound&#8217;s specific storage rules \u2014 neither hMG nor HCG should be frozen reconstituted. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for HPG-Axis and Reproductive Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/hcg-peptide\/\"><strong>HCG (Gonadotrofina Cori\u00f4nica Humana)<\/strong><\/a> \u2014 Agonista puro do receptor LH\/CG \u2014 compara\u00e7\u00e3o direta; atividade apenas do lado do LH<\/li>\n<li><a href=\"\/pt-br\/kisspeptin-10\/\"><strong>Kisspeptina-10<\/strong><\/a> \u2014 Agonista Kiss1R hipotal\u00e2mico \u2014 regulador do eixo HPG a montante, estimula a pulsatileidade do GnRH<\/li>\n<li><a href=\"\/pt-br\/pt-141\/\"><strong>PT-141 (Bremelanotide)<\/strong><\/a> \u2014 Melanocortin-4 receptor agonist \u2014 sexual-function studies<\/li>\n<li><a href=\"\/pt-br\/oxytocin-acetate\/\"><strong>Acetato de Ocitocina<\/strong><\/a> \u2014 Posterior pituitary nonapeptide \u2014 reproductive and social bonding<\/li>\n<li><a href=\"\/pt-br\/tesamorelin\/\"><strong>Tesamorelina<\/strong><\/a> \u2014 An\u00e1logo do GHRH \u2014 eixo end\u00f3crino diferente, comumente coestudado<\/li>\n<li><a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necess\u00e1rio para reconstituir qualquer frasco liofilizado \u2014 diluente est\u00e9ril, preservado com 0,9% de \u00e1lcool benz\u00edlico<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Prepara\u00e7\u00e3o de glicoprote\u00edna hormonal dupla LH + FSH \u2014 propor\u00e7\u00e3o de bioatividade 1:1 (75 UI cada)<br \/>\n\u2705 Agonista dual de receptores de gonadotropina LHCGR + FSHR can\u00f4nico<br \/>\n\u2705 Menotropina extra\u00edda da urina de pool p\u00f3s-menopausa (CAS 61489-71-2)<br \/>\n\u2705 Modelo de duas c\u00e9lulas e duas gonadotropinas \u2014 envolve Leydig+Sertoli ou teca+granulosa<br \/>\n\u2705 Standard tool for spermatogenesis-induction &amp; ovarian-stimulation studies<\/p>\n<p><strong>HMG (Pharmaceutical Grade)<\/strong> cont\u00e9m Gonadotropina Menop\u00e1usica Humana extra\u00edda da urina (menotropina).<\/p>","protected":false},"featured_media":71453,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6490,6495,6492,6497,6498,6496,6493,6494],"class_list":["post-71441","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-gonadotropin","product_tag-hmg","product_tag-hpg-axis","product_tag-human-menopausal-gonadotropin","product_tag-lhcgr-fshr-agonist","product_tag-menotropin","product_tag-reproductive-research","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/71441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=71441"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/71453"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=71441"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=71441"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=71441"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=71441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}